The US Food and Drug Administration (FDA) has approved Gilead Sciences' injectable product, Yeztugo (lenacapavir), as a ...

Gilead Sciences (NasdaqGS:GILD) recently achieved FDA approval for Yeztugo, a significant step in HIV prevention as the first ...

Gilead Sciences has received US FDA approval for Yeztugo, its bi-annual HIV prevention injection, which has shown 96 per cent ...

He affirmed that the new drug "could take the epidemic to the history books," according to Mother Jones.Yeztugo, based on the ...

Approval of first twice-yearly HIV pre-exposure prophylaxis was based on results from the Phase III PURPOSE 1 and PURPOSE 2 ...

With the FDA’s much-anticipated nod for Gilead Sciences’ long-acting HIV pre-exposure prophylaxis (PrEP) injection Yeztugo ...

Gilead Sciences’ twice-yearly injectable pre-exposure prophylaxis (PrEP) drug has been approved by the US Food and Drug ...

The US Food and Drug Administration (FDA) has approved Gilead Sciences (Nasdaq: GILD) Yeztugo (lenacapavir) - the company’s ...

Gilead Sciences’ Yeztugo receives nod; the first and only US FDA-approved HIV prevention option offering 6 months of protection: Foster City, California Friday, June 20, 2025, 1 ...

The clearance ushers in a closely-watched launch for Gilead, which aims to show a long-acting injection can upend a market ...

Gilead Sciences, Inc., a biopharmaceutical company, has received approval from the U.S. Food and Drug Administration (FDA) ...

Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be ...